With increasing awareness of the potential adverse effects associated with high dose EPO treatment, investigations of EPO therapy for neurological disorders such as stroke and schizophrenia are on-going with consideration given to exclusion of treatment with TPA, EPO modifications to minimize changes in hematocrit, and combination therapy with other hormones [195–199]. This evidence concerns the gene EPO and nervous system disorder.